Springer Nature is making Coronavirus research free. View research | View latest news | Sign up for updates

Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy

  • 35 Accesses

  • 13 Citations


We treated 33 patients with liver metastases from breast cancer by immuno-chemotherapy including adoptive cell transfer between 1987 and 1992. In this study, we examined the change of immunological parameters in the peripheral blood lymphocytes and interleukin-2 (IL-2)-cultured lymphocytes, in primary vs. metastatic breast cancer patients and before vs. after treatment. Moreover, we examined their correlation with therapeutic response and survival after treatment. The immunological parameters used werein vitro natural killer cell activity (% lysis of K562),in vitro autologous tumor-killing activity (% lysis against autologous freshly isolated tumor cells), and proliferation of lymphocytes stimulated with IL-2 and autologous sonicated tumor extract antigen in mixed culture (IL-2-enhanced MLTR). When compared with primary breast cancer patients, patients with liver metastases showed a significant decrease in % lysis of K562 and autologous tumor cells. After treatment, the stimulation index in IL-2-enhanced MLTR increased significantly from the pretreatment level and correlated with survival after treatment. Moreover, non-specific immunological parameters (performance status, lymphocyte count, and transferred cell count and proliferation rate of cultured lymphocytes) were significantly associated with response and prognosis.

This is a preview of subscription content, log in to check access.


  1. 1.

    Clark GM, Sledge GW, Osborne CK, McGuire WL: Survival from first recurrence: Relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 5: 55–61, 1987

  2. 2.

    Okino T, Kan N, Nakanishi M, Satoh K, Mise K, Teramura Y, Yamasaki S, Hori T, Kodama H, Ohgaki K, Tobe T: The therapeutic effect of OK-432-combined adoptive immunotherapy against liver metastases from breast cancer. J Cancer Res Clin Oncol 116: 197–202, 1990

  3. 3.

    Yamasaki S, Okino T, Kan N, Satoh K, Mise K, Teramura Y, Harada T, Kodama H, Hori T, Ohgaki K, Tobe T: Factors influencing the response and survival of patients with liver metastases from breast cancer receiving OK-432-combined adoptive immunotherapy. J Cancer Res Clin Oncol 118: 157–162, 1992

  4. 4.

    Okamoto H, Minami M, Shoin S, Koshimura S, Shimizu R: Experimental anticancer studies, part XXXI. On the streptococcal preparation having potent anticancer activity. Jpn J Exp Med 36: 175–186, 1966

  5. 5.

    Talmadge JE, Herberman RB: The preclinical screening laboratory: Evaluation of immunomodulatory and therapeutic properties of biological response modifiers. Cancer Treat Rep 70: 171–182, 1986

  6. 6.

    Hoshino T, Iho S, Kura F, Uchida A:In vivo andin vitro biological effects of OK-432, a streptococcal preparation, on the augmentation of autologous tumor cell killing activity and cytokine production of lymphocytes and monocytes in malignant diseases. In: Micksche M, Klein E (eds) OK-432: A biological response modifier. Professional Postgraduate Services, Tokyo, 1986, pp 61–68

  7. 7.

    Kan N, Hori T, Okino T, Imai S, Ohgaki K, Tobe T: Synergistic anti-tumor effect of host's lymphocytes and lymphocytes cultured with IL-2 and OK-432-combined adoptive immunotherapy. In: Latis K (ed) The 14th International Cancer Congress. Karger, Basel, 1986, p 144

  8. 8.

    Hori T, Mise K, Kan N, Okino T, Satoh K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Kodama H, Tobe T: Therapeutic and life-prolonging effect of intrapleural injection with a streptococcal preparation, OK-432, and IL2-cultured effusion lymphocytes to breast cancer patients with malignant pleural effusion. Biotherapy 5: 21–29, 1992

  9. 9.

    Kan N, Okino T, Nakanishi M, Sato K, Mise K, Yamasaki S, Teramura Y, Ohgaki K, Tobe T: Therapeutic efficacy of sequential therapy with OK-432, cyclophosphamide, IL2-cultured lymphocytes andin vivo IL2 against advanced murine plasmacytoma. Biotherapy 1: 197–206, 1989

  10. 10.

    Ortaldo JR, Wintrout RH: Implications of potential positive correlation between autologous tumor-cell-killing activity and prognosis in lung cancer. J Natl Cancer Inst 82: 1663–1665, 1990

  11. 11.

    Uchida A, Kariya Y, Okamoto N, Sugie K, Fujimoto T, Yagita M: Prediction of postoperative clinical course by autologous tumor-killing activity in lung cancer patients. J Natl Cancer Inst 82: 1697–1701, 1990

  12. 12.

    Talmadge JE: Development of immunotherapeutic strategies for the treatment of malignant neoplasms. Biotherapy 4: 215–236, 1992

  13. 13.

    Nakanishi M, Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Ohgaki K, Tobe T: Comparison between crude interleukin-2 and recombinant interleukin-2 in maintaining killing activity of cultured lymphocytes. Biotherapy 2: 21–32, 1990

  14. 14.

    Morgan DA, Ruscetti FW, Gallo RC: Selectivein vitro growth of T lymphocytes from normal human bone marrows. Science 193: 1007–1008, 1976

  15. 15.

    Gillis S, Smith KA: Long term culture of tumour-specific cytotoxic T cells. Nature 268: 154–156, 1977

  16. 16.

    Kan N, Ohgaki K, Inamoto T, Kodama H: Anti-tumor and therapeutic effects of spleen cells from tumor-bearing mice cultured with T cell growth factor and soluble tumor extract. Cancer Immunol Immunother 18: 215–222, 1984

  17. 17.

    Inamoto T, Ohgaki K, Hikasa Y, Kodama H: Specific antitumor immunity in pre- and postoperative state and five year survival of breast cancer patients. Arch Jpn Chir 53: 345–352, 1984

  18. 18.

    Kan N, Okino T, Kodama H, Ohgaki K, Tobe T, Inamoto T: Breast cancer-specific immunity evaluated by a newin vitro method, IL-2 enhanced MLTR. J Jpn Surg Soc 88: 1624–1631, 1987

  19. 19.

    Peetz M, Swanson J, Moseley HS, Fletcher WS: Endocrine ablation and hepatic artery infusion in the treatment of metastases to the liver from carcinoma of the breast. Surg Gynecol Obstet 155: 395–400, 1982

  20. 20.

    Zinser JW, Hortobagyi GN, Buzdar AU, Smith TL, Fraschini G: Clinical course of breast cancer patients with liver metastases. J Clin Oncol 5: 773–782, 1987

  21. 21.

    Stehlin JS, Ipolyi PD, Greeff P, McGaff CJ, Davis BR, McNary L: Treatment of cancer of the liver: twenty years' experience with infusion and resection in 414 patients. Ann Surg 208: 23–35, 1988

  22. 22.

    Rosenberg SA: Immunotherapy and gene therapy of cancer. Cancer Res (suppl) 51: 5074s-5079s, 1991

  23. 23.

    North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T-cells. J Exp Med 155: 1063–1074, 1982

  24. 24.

    Livingston PO, Cunningham-Rundles S, Marfleet G, Gnecco C, Wong GY, Schiffman G, Enker WE, Hoffman MK: Inhibition of suppressor-cell activity by cyclophosphamide in patients with malignant melanoma. J Biol Response Mod 6: 392–403, 1987

  25. 25.

    Formelli F, Rossi C, Sensi ML, Parmiani G: Potentiation of adoptive immunotherapy by cis-diamminedichloroplatinum(II), but not by doxorubicin, on a disseminated mouse lymphoma and its association with reduction of tumor burden. Int J Cancer 42: 952–957, 1988

  26. 26.

    Kan N, Okino T, Kodama H, Satoh K, Mise K, Yamasaki S, Teramura Y, Harada T, Ohgaki K, Tobe T: Long-term survival of patients with advanced breast cancer in relation to IL-2-added MLTR. Biotherapy 6: 672–674, 1992

Download references

Author information

Correspondence to Norimichi Kan.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Yamasaki, S., Kan, N., Harada, T. et al. Relationship between immunological parameters and survival of patients with liver metastases from breast cancer given immuno-chemotherapy. Breast Cancer Res Tr 26, 55–65 (1993). https://doi.org/10.1007/BF00682700

Download citation

Key words

  • autologous tumor killing activity
  • breast cancer
  • immuno-chemotherapy
  • interleukin-2
  • mixed lymphocyte tumor reaction
  • natural killer cell activity